cermaVEIN
This article was originally published in Start Up
Executive Summary
Treatment for often painful and unsightly varicose veins involves shutting down defective veins and rerouting the blood to nearby healthy veins. For the most prevalent type of varicose vein, the greater saphenous vein. the standard of care is endovascular thermal ablation, whereby the vein is heated from the inside, boiling the blood and sealing the vein closed. But nstead of using RF or laser energy to heat the vein by inserting a catheter with a guidewire, cermaVEIN has found success with simple steam ablation, which avoids boiling the blood and does not require a guidewire.
You may also be interested in...
Start-Up Previews (10/2011)
This Month's Profile Group: The New Ophthalmic Drug Players, features profiles of Imagen Biotech, KalVista Pharmaceuticals, ONL Therapeutics and Xcovery Vision. Plus these Start-Ups Across Health Care: Acetylon Pharmaceuticals, Aleva Neurotherapeutics, cermaVEIN and Flex Biomedical.
Start-Up Previews (10/2011)
This Month's Profile Group: The New Ophthalmic Drug Players, features profiles of Imagen Biotech, KalVista Pharmaceuticals, ONL Therapeutics and Xcovery Vision. Plus these Start-Ups Across Health Care: Acetylon Pharmaceuticals, Aleva Neurotherapeutics, cermaVEIN and Flex Biomedical.
Vein Device Companies Dig Deeper
Vein diseases such as deep vein thrombosis, pulmonary embolism and chronic venous insufficiency have historically been the province of drug therapies, but they shouldn't be, according to the clinical socieities and medical device companies that are trying to create a groundswell in interventional vein treatments. The field is starting to organize: on the clinical side, the first clinical trials ever to pit devices against drugs for DVT are in progress. At the same time, Covidien has drawn attention to the business opportunities in the field by acquiring three companies with venous devices.